Financials data is unavailable for this security.
View more
Year on year Dr Reddy's Laboratories Ltd grew revenues 13.54% from 245.88bn to 279.16bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 23.56% net income growth from 45.07bn to 55.68bn.
| Gross margin | 59.29% |
|---|---|
| Net profit margin | 18.07% |
| Operating margin | 22.58% |
| Return on assets | 13.33% |
|---|---|
| Return on equity | 19.10% |
| Return on investment | 18.20% |
More ▼
Cash flow in INRView more
In 2024, Dr Reddy's Laboratories Ltd increased its cash reserves by 22.98%, or 1.33bn. The company earned 45.43bn from its operations for a Cash Flow Margin of 16.27%. In addition the company used 40.28bn on investing activities and also paid 3.76bn in financing cash flows.
| Cash flow per share | 0.9876 |
|---|---|
| Price/Cash flow per share | 14.55 |
| Book value per share | 4.34 |
|---|---|
| Tangible book value per share | 2.87 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.92 |
|---|---|
| Quick ratio | 1.34 |
| Total debt/total equity | 0.159 |
|---|---|
| Total debt/total capital | 0.1357 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 29.38% and 23.32%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 0.63% |
|---|---|
| Div growth rate (5 year) | 14.77% |
| Payout ratio (TTM) | 12.54% |
| EPS growth(5 years) | 24.18 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 4.67 |
More ▼
